全文获取类型
收费全文 | 230篇 |
免费 | 17篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 46篇 |
临床医学 | 14篇 |
内科学 | 31篇 |
皮肤病学 | 3篇 |
神经病学 | 19篇 |
特种医学 | 6篇 |
外科学 | 23篇 |
综合类 | 2篇 |
预防医学 | 6篇 |
眼科学 | 1篇 |
药学 | 3篇 |
肿瘤学 | 86篇 |
出版年
2022年 | 1篇 |
2021年 | 6篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 7篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 11篇 |
2012年 | 16篇 |
2011年 | 17篇 |
2010年 | 15篇 |
2009年 | 6篇 |
2008年 | 11篇 |
2007年 | 19篇 |
2006年 | 16篇 |
2005年 | 16篇 |
2004年 | 21篇 |
2003年 | 12篇 |
2002年 | 18篇 |
2001年 | 6篇 |
2000年 | 10篇 |
1999年 | 6篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1992年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有248条查询结果,搜索用时 29 毫秒
101.
Paulo Vidal Campregher Welbert de Oliveira Pereira Bianca Lisboa Renato Puga Elvira Rodrigues Pereira Velloso Deolinda Ricardo Helman Luciana Cavalheiro Marti Jo?o Carlos Campos Guerra Kalliopi N. Manola Roberta Cardoso Petroni Alanna Mara Pinheiro Sobreira Bezerra Fernando Ferreira Costa Nelson Hamerschlak Fábio Pires de Souza Santos 《Haematologica》2016,101(7):e287-e290
102.
103.
Betti Schopp Barbara Holz Manola Zago Frank Stubenrauch Karl‐Ulrich Petry Susanne Krüger Kjaer Thomas Iftner 《Journal of medical virology》2010,82(4):605-615
The novel PapilloCheck® genotyping test was compared with SPF10 PCR LiPav1 and PGMY09/11 on hybrid capture 2 (HC2)‐pretested samples. From results of 826 cervical samples detection rates and kappa values for the tests were calculated using a HPV type consensus definition. With PapilloCheck® HPV types 53, 56, and 33 were found with a sensitivity of 100%. The lowest detection rate was observed for HPV 35 (72.2%). The SPF10 PCR LiPav1 was found to be 100% positive for HPV 18, 31, 53, 56, and 35 and lowest for HPV 59 (81%). The PGMY09/11 system detected only HPV 59 at 100% detection rate and showed lowest sensitivity for HPV 56 (40.5%). Multiple infection rates ranged from 25.8% (PGMY09/11 PCR‐LBA), over 39.5% (PapilloCheck®) to 55.9% (SPF10 PCR LiPav1). In samples with higher viral DNA load detection rates and concordance between the genotyping tests increases. The kappa values in comparison to the HPV consensus type ranged from k = 0.21 to k = 0.82 for comparing SPF10 PCR with the HPV consensus type, while values for PGMY09/11 PCR ranged from k = 0 to k = 0.96 and were best for the PapilloCheck® (k = 0.49–0.98). Detection rates for the identification of high‐grade cervical intraepithelial neoplasia (CIN2+) ranged from 93.7% (PGMY09/11 PCR) to 98.4% (PapilloCheck®, SPF10 PCR, HC2). In conclusion, this study shows that the PapilloCheck® give comparable results to established PCR methods. However, these results also show a necessity for the standardization of genotype‐specific HPV detection assays. J. Med. Virol. 82:605–615, 2010. © 2010 Wiley‐Liss, Inc. 相似文献
104.
105.
106.
DNA is subjected to several modifications, resulting from endogenous and exogenous sources. The cell has developed a network of complementary DNA-repair mechanisms, and in the human genome, >130 genes have been found to be involved. Knowledge about the basic mechanisms for DNA repair has revealed an unexpected complexity, with overlapping specificity within the same pathway, as well as extensive functional interactions between proteins involved in repair pathways. Unrepaired or improperly repaired DNA lesions have serious potential consequences for the cell, leading to genomic instability and deregulation of cellular functions. A number of disorders or syndromes, including several cancer predispositions and accelerated aging, are linked to an inherited defect in one of the DNA-repair pathways. Genomic instability, a characteristic of most human malignancies, can also arise from acquired defects in DNA repair, and the specific pathway affected is predictive of types of mutations, tumor drug sensitivity, and treatment outcome. Although DNA repair has received little attention as a determinant of drug sensitivity, emerging knowledge of mutations and polymorphisms in key human DNA-repair genes may provide a rational basis for improved strategies for therapeutic interventions on a number of tumors and degenerative disorders. 相似文献
107.
Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma 总被引:1,自引:0,他引:1
Chandrajit P. Raut Marisa R. Nucci Qian Wang Judith Manola Monica M. Bertagnolli George D. Demetri Jeffrey A. Morgan Michael G. Muto Christopher D.M. Fletcher Suzanne George 《European journal of cancer (Oxford, England : 1990)》2009,45(16):2818-2824
BackgroundCancer staging systems aim to identify patient cohorts with different outcomes based on clinically relevant prognostic factors. Uterine leiomyosarcoma (ULMS) is classified using the FIGO staging system developed for epithelial malignancies; other sarcomas use the AJCC staging system. Neither has been validated in ULMS. We critically evaluated both systems to determine if either identified patient groups with distinct outcomes.MethodsWe staged 230 ULMS patients by the FIGO and AJCC systems. Progression-free survival (PFS) and overall survival (OS) rates were calculated; statistical pairwise comparisons were performed.ResultsThe number of stages I and III patients varied by staging system. There were few stage II patients by either system. Using the FIGO system, PFS was better in stage I patients versus stage III or IV patients, and OS was better in stage I patients versus stage IV patients. Using the AJCC system, PFS and OS were better in stage I patients (low grade) versus stage II, III or IV patients, and OS was better in stage III patients versus stage IV patients. Prognosis of patients with serosal involvement (FIGO III) was similar to that of patients with metastases (FIGO IV).ConclusionNeither system classifies ULMS patients into four clinically meaningful, non-overlapping stages predictive of PFS and OS. This analysis highlights the relevance of certain factors (low grade, serosal involvement) and rarity of others (FIGO stage II, cervical invasion). Once identified, prognostic factors relevant to this malignancy should be incorporated into a new staging system in an effort to identify appropriate cohorts for different treatments. 相似文献
108.
Manola KN Sambani C Karakasis D Kalliakosta G Harhalakis N Papaioannou M 《Leukemia research》2008,32(3):481-486
Cases of leukemia associated with Turner syndrome (TS) are rare. Here we report three TS patients with leukemia including one case of T-large granular lymphocyte leukemia (T-LGL), one rare case of coexistence of chronic lymphocytic leukemia (CLL) and idiopathic myelofibrosis (IMF) and one case of a patient with AML-M2 who received autologous stem cell transplantation (SCT). T-LGL and coexistence of CLL and IMF associated with TS are reported for the first time while the last case represents the first report of SCT in a leukemia patient with TS. Our cases and the limited data of previously reported leukemia patients with TS suggest that TS is not associated with a specific type of leukemia and that presentation, clinical course and response to treatment are similar to that of the non-TS leukemia patients. However, these patients may have a higher risk of liver complications. Interestingly, in the mosaic TS patients, the abnormal clones were restricted to the monosomic 45,X cells, indicating that the leukemic clones possibly originate from the monosomic cell line. Even in cases with no additional chromosome abnormalities, the ratio of X/XX cells in bone marrow cells was significantly increased compared to that in constitutional karyotype, indicating that monosomic cells possibly provide a survival advantage for leukemia cells or that reduced programmed cell death may be responsible for the expansion of the monosomic cells. 相似文献
109.